Metabolic network failures in Alzheimer's disease: A biochemical road map

Alzheimer's and Dementia

Volumn 13, Issue 9, 2017, Pages 965-984

  Toledo, Jon B ^a,b   Arnold, Matthias ^c   Kastenmüller, Gabi ^c,d   Chang, Rui ^e   Baillie, Rebecca A ^f   Han, Xianlin ^g   Thambisetty, Madhav ^h   Tenenbaum, Jessica D ⁱ   Suhre, Karsten ^c,j   Thompson, J Will ^k   John Williams, Lisa St ^k   MahmoudianDehkordi, Siamak ^l   Rotroff, Daniel M ^l   Jack, John R ^l   Motsinger Reif, Alison ^l   Risacher, Shannon L ^m   Blach, Colette ⁱ   Lucas, Joseph E ^k   Massaro, Tyler ^k   Louie, Gregory ⁱ   Zhu, Hongjie ⁱ   Dallmann, Guido ⁿ   Klavins, Kristaps ⁿ   Koal, Therese ⁿ   Kim, Sungeun ^m   Nho, Kwangsik ^m   Shen, Li ^m   Casanova, Ramon ^h   Varma, Sudhir ^h   Legido Quigley, Cristina ^o   Moseley, M Arthur ^k   Zhu, Kuixi ^e   Henrion, Marc Y R ^e   van der Lee, Sven J ^p   Harms, Amy C ^q   Demirkan, Ayse ^p   Hankemeier, Thomas ^p,q   van Duijn, Cornelia M ^p,q   Trojanowski, John Q ^a   Shaw, Leslie M ^a   Saykin, Andrew J ^m   Weiner, Michael W ^r   Doraiswamy, P Murali ⁱ   Kaddurah Daouk, Rima ^i,s   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f Rosa and Co LLC   (United States)

^g BURNHAM INSTITUTE   (United States)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

ⁱ DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^k DUKE UNIVERSITY   (United States)

^l NORTH CAROLINA STATE UNIVERSITY   (United States)

^m INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ BIOCRATES LIFE SCIENCES AG   (Austria)

^o KING'S COLLEGE LONDON   (United Kingdom)

^p ERASMUS MEDICAL CENTER   (Netherlands)

^q LEIDEN UNIVERSITY   (Netherlands)

^r UNIVERSITY OF CALIFORNIA   (United States)

^s DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Acylcarnitines; Alzheimer's disease; Biochemical networks; Biomarkers; Branched chain amino acids; Dementia; Metabolism; Metabolomics; Metabonomics; Pharmacometabolomics; Pharmacometabonomics; Phospholipids; Precision medicine; Serum; Sphingomyelins; Systems biology

Indexed keywords

2 AMINOADIPIC ACID; ACYLCARNITINE; AMYLOID BETA PROTEIN[1-42]; GLUTAMIC ACID; GLYCINE; HISTIDINE; ISOLEUCINE; PHOSPHATIDYLCHOLINE; PROLINE; SPHINGOMYELIN; TAU PROTEIN; TRYPTOPHAN; TYROSINE; VALINE; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; AMINO ACID; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); ANILINE DERIVATIVE; PEPTIDE FRAGMENT; THIAZOLE DERIVATIVE;

ALZHEIMER DISEASE; ARTICLE; BIOCHEMICAL ANALYSIS; BRAIN ATROPHY; BRAIN METABOLISM; BRAIN SIZE; BRAIN VENTRICLE; CEREBROSPINAL FLUID; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; METABOLOMICS; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; AGED; AGING; BLOOD; COGNITIVE DEFECT; COMPLICATION; CROSS-SECTIONAL STUDY; DIAGNOSTIC IMAGING; DIET RESTRICTION; FEMALE; MALE; METABOLIC DISORDER; METABOLISM; PHYSIOLOGY; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; AMINO ACIDS; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; COGNITIVE DYSFUNCTION; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FASTING; FEMALE; HUMANS; MALE; METABOLIC DISEASES; METABOLIC NETWORKS AND PATHWAYS; METABOLOMICS; PEPTIDE FRAGMENTS; PHOSPHATIDYLCHOLINES; SPHINGOMYELINS; TAU PROTEINS; THIAZOLES;

EID: 85015733333     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2017.01.020     Document Type: Article

References (80)

1. Citron, M., Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 9 (2010), 387–398.
2. Cai, H., Cong, W.N., Ji, S., Rothman, S., Maudsley, S., Martin, B., Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders. Curr Alzheimer Res 9 (2012), 5–17.
3. de la Monte, S.M., Tong, M., Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem Pharmacol 88 (2014), 548–559.
4. Procaccini, C., Santopaolo, M., Faicchia, D., Colamatteo, A., Formisano, L., de Candia, P., et al. Role of metabolism in neurodegenerative disorders. Metabolism 65 (2016), 1376–1390.
5. Chen, Z., Zhong, C., Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog Neurobiol 108 (2013), 21–43.
6. Patti, G.J., Yanes, O., Siuzdak, G., Innovation: metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol 13 (2012), 263–269.
7. Kaddurah-Daouk, R., Krishnan, K.R., Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology 34 (2009), 173–186.
8. Kaddurah-Daouk, R., Weinshilboum, R., Metabolomic signatures for drug response phenotypes: pharmacometabolomics enables precision medicine. Clin Pharmacol Ther 98 (2015), 71–75.
9. Kaddurah-Daouk, R., Weinshilboum, R.M., Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. Clin Pharmacol Ther 95 (2014), 154–167.
10. Han, X., Rozen, S., Boyle, S.H., Hellegers, C., Cheng, H., Burke, J.R., et al. Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One, 6, 2011, e21643.
11. Casanova, R., Varma, S., Simpson, B., Kim, M., An, Y., Saldana, S., et al. Blood metabolite markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older individuals. Alzheimers Dement 12 (2016), 815–822.
12. Fiandaca, M.S., Zhong, X., Cheema, A.K., Orquiza, M.H., Chidambaram, S., Tan, M.T., et al. Plasma 24-metabolite panel predicts preclinical transition to clinical stages of Alzheimer's disease. Front Neurol, 6, 2015, 237.
13. Klavins, K., Koal, T., Dallmann, G., Marksteiner, J., Kemmler, G., Humpel, C., The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairment. Alzheimers Dement (Amst) 1 (2015), 295–302.
14. Koal, T., Klavins, K., Seppi, D., Kemmler, G., Humpel, C., Sphingomyelin SM(d18:1/18:0) is significantly enhanced in cerebrospinal fluid samples dichotomized by pathological amyloid-beta42, tau, and phospho-tau-181 levels. J Alzheimers Dis 44 (2015), 1193–1201.
15. Mapstone, M., Cheema, A.K., Fiandaca, M.S., Zhong, X., Mhyre, T.R., MacArthur, L.H., et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 20 (2014), 415–418.
16. Motsinger-Reif, A.A., Zhu, H., Kling, M.A., Matson, W., Sharma, S., Fiehn, O., et al. Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer's disease from normal cognitive aging. Acta Neuropathol Commun, 1, 2013, 28.
17. Kaddurah-Daouk, R., Rozen, S., Matson, W., Han, X., Hulette, C.M., Burke, J.R., et al. Metabolomic changes in autopsy-confirmed Alzheimer's disease. Alzheimers Dement 7 (2011), 309–317.
18. Kaddurah-Daouk, R., Zhu, H., Sharma, S., Bogdanov, M., Rozen, S.G., Matson, W., et al. Alterations in metabolic pathways and networks in Alzheimer's disease. Transl Psychiatry, 3, 2013, e244.
19. Gonzalez-Dominguez, R., Garcia-Barrera, T., Vitorica, J., Gomez-Ariza, J.L., Metabolomic investigation of systemic manifestations associated with Alzheimer's disease in the APP/PS1 transgenic mouse model. Mol Biosyst 11 (2015), 2429–2440.
20. Soltow, Q.A., Jones, D.P., Promislow, D.E., A network perspective on metabolism and aging. Integr Comp Biol 50 (2010), 844–854.
21. Simpson, B.N., Kim, M., Chuang, Y.F., Beason-Held, L., Kitner-Triolo, M., Kraut, M., et al. Blood metabolite markers of cognitive performance and brain function in aging. J Cereb Blood Flow Metab 36 (2016), 1212–1223.
22. Han, X., Holtzman, D.M., McKeel, D.W. Jr., Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J Neurochem 77 (2001), 1168–1180.
23. Wood, P.L., Smith, T., Lane, N., Khan, M.A., Ehrmantraut, G., Goodenowe, D.B., Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new therapeutic strategy for Alzheimer's disease. Lipids Health Dis, 10, 2011, 227.
24. Ibanez, C., Simo, C., Martin-Alvarez, P.J., Kivipelto, M., Winblad, B., Cedazo-Minguez, A., et al. Toward a predictive model of Alzheimer's disease progression using capillary electrophoresis-mass spectrometry metabolomics. Anal Chem 84 (2012), 8532–8540.
25. Trushina, E., Dutta, T., Persson, X.M., Mielke, M.M., Petersen, R.C., Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics. PLoS One, 8, 2013, e63644.
26. Li, D., Misialek, J.R., Boerwinkle, E., Gottesman, R.F., Sharrett, A.R., Mosley, T.H., et al. Plasma phospholipids and prevalence of mild cognitive impairment and/or dementia in the ARIC Neurocognitive Study (ARIC-NCS). Alzheimers Dement (Amst) 3 (2016), 73–82.
27. Savica, R., Murray, M.E., Persson, X.M., Kantarci, K., Parisi, J.E., Dickson, D.W., et al. Plasma sphingolipid changes with autopsy-confirmed Lewy Body or Alzheimer's pathology. Alzheimers Dement (Amst) 3 (2016), 43–50.
28. Pan, X., Nasaruddin, M.B., Elliott, C.T., McGuinness, B., Passmore, A.P., Kehoe, P.G., et al. Alzheimer's disease-like pathology has transient effects on the brain and blood metabolome. Neurobiol Aging 38 (2016), 151–163.
29. Santiago, J.A., Potashkin, J.A., A network approach to clinical intervention in neurodegenerative diseases. Trends Mol Med 20 (2014), 694–703.
30. Jack, C.R. Jr., Holtzman, D.M., Biomarker modeling of Alzheimer's disease. Neuron 80 (2013), 1347–1358.
31. Weiner, M.W., Veitch, D.P., Aisen, P.S., Beckett, L.A., Cairns, N.J., Cedarbaum, J., et al. Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimers Dement 11 (2015), 865–884.
32. Draisma, H.H., Pool, R., Kobl, M., Jansen, R., Petersen, A.K., Vaarhorst, A.A., et al. Genome-wide association study identifies novel genetic variants contributing to variation in blood metabolite levels. Nat Commun, 6, 2015, 7208.
33. Wurtz, P., Havulinna, A.S., Soininen, P., Tynkkynen, T., Prieto-Merino, D., Tillin, T., et al. Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. Circulation 131 (2015), 774–785.
34. Ikram, M.A., van der Lugt, A., Niessen, W.J., Koudstaal, P.J., Krestin, G.P., Hofman, A., et al. The Rotterdam Scan Study: design update 2016 and main findings. Eur J Epidemiol 30 (2015), 1299–1315.
35. Liu, F., Pardo, L.M., Schuur, M., Sanchez-Juan, P., Isaacs, A., Sleegers, K., et al. The apolipoprotein E gene and its age-specific effects on cognitive function. Neurobiol Aging 31 (2010), 1831–1833.
36. Hoogendam, Y.Y., Hofman, A., van der Geest, J.N., van der Lugt, A., Ikram, M.A., Patterns of cognitive function in aging: the Rotterdam Study. Eur J Epidemiol 29 (2014), 133–140.
37. de Bruijn, R.F., Bos, M.J., Portegies, M.L., Hofman, A., Franco, O.H., Koudstaal, P.J., et al. The potential for prevention of dementia across two decades: the prospective, population-based Rotterdam Study. BMC Med, 13, 2015, 132.
38. Davies, G., Armstrong, N., Bis, J.C., Bressler, J., Chouraki, V., Giddaluru, S., et al. Genetic contributions to variation in general cognitive function: a meta-analysis of genome-wide association studies in the CHARGE consortium (N=53949). Mol Psychiatry 20 (2015), 183–192.
39. Risacher, S.L., Wudunn, D., Pepin, S.M., MaGee, T.R., McDonald, B.C., Flashman, L.A., et al. Visual contrast sensitivity in Alzheimer's disease, mild cognitive impairment, and older adults with cognitive complaints. Neurobiol Aging 34 (2013), 1133–1144.
40. Wang, Y., Risacher, S.L., West, J.D., McDonald, B.C., Magee, T.R., Farlow, M.R., et al. Altered default mode network connectivity in older adults with cognitive complaints and amnestic mild cognitive impairment. J Alzheimers Dis 35 (2013), 751–760.
41. Kim, S., Swaminathan, S., Inlow, M., Risacher, S.L., Nho, K., Shen, L., et al. Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel. PLoS One, 8, 2013, e70269.
42. Ramanan, V.K., Risacher, S.L., Nho, K., Kim, S., Shen, L., McDonald, B.C., et al. GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP. Brain 138 (2015), 3076–3088.
43. Klunk, W.E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D.P., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55 (2004), 306–319.
44. Landau, S.M., Breault, C., Joshi, A.D., Pontecorvo, M., Mathis, C.A., Jagust, W.J., et al. Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med 54 (2013), 70–77.
45. Kang, J.H., Korecka, M., Figurski, M.J., Toledo, J.B., Blennow, K., Zetterberg, H., et al. The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: a review of progress and plans. Alzheimers Dement 11 (2015), 772–791.
46. Shaw, L.M., Vanderstichele, H., Knapik-Czajka, M., Clark, C.M., Aisen, P.S., Petersen, R.C., et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65 (2009), 403–413.
47. Reuter, M., Schmansky, N.J., Rosas, H.D., Fischl, B., Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage 61 (2012), 1402–1418.
48. Fan, Y., Shen, D., Gur, R.C., Gur, R.E., Davatzikos, C., COMPARE: classification of morphological patterns using adaptive regional elements. IEEE Trans Med Imaging 26 (2007), 93–105.
49. Toledo, J.B., Da, X., Bhatt, P., Wolk, D.A., Arnold, S.E., Shaw, L.M., et al. Relationship between plasma analytes and SPARE-AD defined brain atrophy patterns in ADNI. PLoS One, 8, 2013, e55531.
50. Rmetrics Core Team, Wuertz, D., Setz, T., Chalabi, Y., fBasics: Rmetrics - Markets and Basic Statistics. R package version. 2014.
51. D'Agostino, R., Pearson, E.S., Tests for departure from normality. Biometrika 60 (1973), 613–622.
52. Pinheiro, J.C., Bates, D.M., Mixed-effects Models in S and S-PLUS. 2000, Springer Verlag, New York.
53. R Core Team. R: A Language and Environment for Statistical Computing. 2015, R Foundation for Statistical Computing, Vienna, Austria.
54. Langfelder, P., Horvath, S., WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics, 9, 2008, 559.
55. Krumsiek, J., Suhre, K., Illig, T., Adamski, J., Theis, F.J., Gaussian graphical modeling reconstructs pathway reactions from high-throughput metabolomics data. BMC Syst Biol, 5, 2011, 21.
56. Mittelstrass, K., Ried, J.S., Yu, Z., Krumsiek, J., Gieger, C., Prehn, C., et al. Discovery of sexual dimorphisms in metabolic and genetic biomarkers. PLoS Genet, 7, 2011, e1002215.
57. Krumsiek, J., Suhre, K., Evans, A.M., Mitchell, M.W., Mohney, R.P., Milburn, M.V., et al. Mining the unknown: a systems approach to metabolite identification combining genetic and metabolic information. PLoS Genet, 8, 2012, e1003005.
58. Jack, C.R. Jr., Albert, M.S., Knopman, D.S., McKhann, G.M., Sperling, R.A., Carrillo, M.C., et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 257–262.
59. Toledo, J.B., Brettschneider, J., Grossman, M., Arnold, S.E., Hu, W.T., Xie, S.X., et al. CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol 124 (2012), 23–35.
60. Frisardi, V., Panza, F., Seripa, D., Farooqui, T., Farooqui, A.A., Glycerophospholipids and glycerophospholipid-derived lipid mediators: a complex meshwork in Alzheimer's disease pathology. Prog Lipid Res 50 (2011), 313–330.
61. Perttu, E.K., Kohli, A.G., Szoka, F.C. Jr., Inverse-phosphocholine lipids: a remix of a common phospholipid. J Am Chem Soc 134 (2012), 4485–4488.
62. Braverman, N.E., Moser, A.B., Functions of plasmalogen lipids in health and disease. Biochim Biophys Acta 1822 (2012), 1442–1452.
63. Fonteh, A.N., Ormseth, C., Chiang, J., Cipolla, M., Arakaki, X., Harrington, M.G., Sphingolipid metabolism correlates with cerebrospinal fluid Beta amyloid levels in Alzheimer's disease. PLoS One, 10, 2015, e0125597.
64. Gross, R.W., High plasmalogen and arachidonic acid content of canine myocardial sarcolemma: a fast atom bombardment mass spectroscopic and gas chromatography-mass spectroscopic characterization. Biochemistry 23 (1984), 158–165.
65. Heppner, F.L., Ransohoff, R.M., Becher, B., Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 16 (2015), 358–372.
66. Rushworth, J.V., Hooper, N.M., Lipid rafts: linking Alzheimer's amyloid-beta production, aggregation, and toxicity at neuronal membranes. Int J Alzheimers Dis, 2011, 2010, 603052.
67. Whiley, L., Sen, A., Heaton, J., Proitsi, P., Garcia-Gomez, D., Leung, R., et al. Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. Neurobiol Aging 35 (2014), 271–278.
68. McCoin, C.S., Knotts, T.A., Adams, S.H., Acylcarnitines–old actors auditioning for new roles in metabolic physiology. Nat Rev Endocrinol 11 (2015), 617–625.
69. Walter, J., van Echten-Deckert, G., Cross-talk of membrane lipids and Alzheimer-related proteins. Mol Neurodegener, 8, 2013, 34.
70. Jones, L.L., McDonald, D.A., Borum, P.R., Acylcarnitines: role in brain. Prog Lipid Res 49 (2010), 61–75.
71. Yin, F., Yao, J., Sancheti, H., Feng, T., Melcangi, R.C., Morgan, T.E., et al. The perimenopausal aging transition in the female rat brain: decline in bioenergetic systems and synaptic plasticity. Neurobiol Aging 36 (2015), 2282–2295.
72. Stanley, M., Macauley, S.L., Holtzman, D.M., Changes in insulin and insulin signaling in Alzheimer's disease: cause or consequence?. J Exp Med 213 (2016), 1375–1385.
73. Kling, M.A., Trojanowski, J.Q., Wolk, D.A., Lee, V.M., Arnold, S.E., Vascular disease and dementias: paradigm shifts to drive research in new directions. Alzheimers Dement 9 (2013), 76–92.
74. Floegel, A., Stefan, N., Yu, Z., Muhlenbruch, K., Drogan, D., Joost, H.G., et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes 62 (2013), 639–648.
75. Wang, T.J., Larson, M.G., Vasan, R.S., Cheng, S., Rhee, E.P., McCabe, E., et al. Metabolite profiles and the risk of developing diabetes. Nat Med 17 (2011), 448–453.
76. Wang, T.J., Ngo, D., Psychogios, N., Dejam, A., Larson, M.G., Vasan, R.S., et al. 2-Aminoadipic acid is a biomarker for diabetes risk. J Clin Invest 123 (2013), 4309–4317.
77. Kawaguchi, T., Nagao, Y., Matsuoka, H., Ide, T., Sata, M., Branched-chain amino acid-enriched supplementation improves insulin resistance in patients with chronic liver disease. Int J Mol Med 22 (2008), 105–112.
78. Ruiz, H.H., Chi, T., Lindtner, C., Hsieh, W., Shin, A.C., Ehrlich, M., et al. Increased susceptibility to metabolic dysregulation in a mouse model of Alzheimer's disease is associated with impaired hypothalamic insulin signaling and elevated BCAA levels. Alzheimers Dement 12 (2016), 851–861.
79. Jha, S.K., Jha, N.K., Kumar, D., Ambasta, R.K., Kumar, P., Linking mitochondrial dysfunction, metabolic syndrome and stress signaling in Neurodegeneration. Biochim Biophys Acta, 2016 pii: S0925-4439(16)30157-0.
80. Koliaki, C., Roden, M., Alterations of mitochondrial function and insulin sensitivity in human obesity and diabetes mellitus. Annu Rev Nutr 36 (2016), 337–367.